Oncology

Back to articles

Antibody-drug conjugates provide new option for HER2-positive breast cancer

KEY POINT

In patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with trastuzumab (Herceptin—Genentech) and a taxane, use of ado-trastuzumab emtansine (Kadcyla—Genentech) significantly prolonged progression-free survival and overall survival as compared to lapatinib (Tykerb—GlaxoSmithKline) plus capecitabine (Xeloda—Roche). Ado-trastuzumab emtansine was associated with less toxicity than lapatinib plus capecitabine.

SOURCES

Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;267:1783–91.

Teicher BA et al. The promise of antibody–drug conjugates [editorial]. N Engl J Med. 2012;367:1847–8.